August 4, 2015 (Shareholders Foundation) - An investigation for investors who purchased shares of OvaScience Inc (NASDAQ:OVAS) in the secondary offering was initiated over potential securities laws violations in connection certain financial statements.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OvaScience Inc (NASDAQ:OVAS) concerning whether certain statements in connection with the Secondary Offering were materially false and misleading at the time they were made.

On January 8, 2015, OvaScience Inc conducted a Secondary Offering (the 'Offering'), selling 2.3 million shares of the Company's common stock at $50 per share.

On March 26, 2015, OvaScience Inc announced that presentations by fertility specialists offering the Companys AUGMENTSM fertility treatment reported encouraging pregnancy rates in women who previously failed multiple cycles of in vitro fertilization (IVF). OvaScience Inc said that Clinical reports from two international IVF clinics will be featured at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting.

On Mar. 28, 2015, OvaScience Inc announced that additional clinical experience of the Companys AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven prior in vitro fertilization (IVF) cycles. OvaScience Inc said that these results were reported at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting being held in San Francisco, CA.

Shares of OvaScience Inc (NASDAQ:OVAS) declined from as high as $53.46 per share on March 24, 2015 to as low as $24.49 per share on May 6, 2015.